JP2014510110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510110A5 JP2014510110A5 JP2014501296A JP2014501296A JP2014510110A5 JP 2014510110 A5 JP2014510110 A5 JP 2014510110A5 JP 2014501296 A JP2014501296 A JP 2014501296A JP 2014501296 A JP2014501296 A JP 2014501296A JP 2014510110 A5 JP2014510110 A5 JP 2014510110A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- disorder
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FOWGTUFARAVWSI-UHFFFAOYSA-N CCO.OCC(N)(C)C(O)O.OCC(N)(C)C(O)O Chemical class CCO.OCC(N)(C)C(O)O.OCC(N)(C)C(O)O FOWGTUFARAVWSI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000037365 barrier function of the epidermis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467404P | 2011-03-25 | 2011-03-25 | |
| US61/467,404 | 2011-03-25 | ||
| PCT/US2012/030499 WO2012135082A1 (en) | 2011-03-25 | 2012-03-26 | Prodrugs of lxr modulating imidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510110A JP2014510110A (ja) | 2014-04-24 |
| JP2014510110A5 true JP2014510110A5 (enExample) | 2015-03-19 |
Family
ID=45926934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501296A Pending JP2014510110A (ja) | 2011-03-25 | 2012-03-26 | Ｌｘｒ調節イミダゾール誘導体のプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8901106B2 (enExample) |
| EP (1) | EP2688871B1 (enExample) |
| JP (1) | JP2014510110A (enExample) |
| CN (1) | CN103443082B (enExample) |
| AR (1) | AR088728A1 (enExample) |
| ES (1) | ES2548050T3 (enExample) |
| TW (1) | TW201242953A (enExample) |
| WO (1) | WO2012135082A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2820013T3 (pl) | 2012-03-02 | 2019-01-31 | Ralexar Therapeutics, Inc. | Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych |
| HUE046292T2 (hu) | 2012-08-13 | 2020-02-28 | Univ Rockefeller | Melanóma kezelése és diagnosztizálása |
| EP2968275B1 (en) * | 2013-03-15 | 2017-11-29 | Bristol-Myers Squibb Company | Lxr modulators |
| SG11201601644RA (en) | 2013-09-04 | 2016-04-28 | Alexar Therapeutics Inc | Liver x receptor (lxr) modulators |
| ES2804304T3 (es) | 2013-09-04 | 2021-02-05 | Ellora Therapeutics Inc | Moduladores del receptor X hepático (LXR) |
| AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| CR20170167A (es) | 2014-10-03 | 2017-08-10 | Sanofi Sa | Derivados de imidazol pentacíclicos fusionados |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| EA201892149A1 (ru) | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
| WO2017167995A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused hexacyclic imidazole derivatives as modulators of tnf activity |
| CA3019026A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| EP3436460B1 (en) | 2016-04-01 | 2021-08-18 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| MA44629A (fr) * | 2016-04-04 | 2021-03-24 | Chemocentryx Inc | Antagonistes de c5ar solubles |
| WO2018167176A1 (en) | 2017-03-15 | 2018-09-20 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| PL4073025T3 (pl) | 2019-12-13 | 2024-09-16 | Inspirna, Inc. | Sole metali i ich zastosowania |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| HU204253B (en) | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| AU2579692A (en) | 1991-09-17 | 1993-04-27 | Salk Institute For Biological Studies, The | Receptor of the thyroid/steroid hormone receptor superfamily |
| HUP0001938A3 (en) | 1997-01-24 | 2001-09-28 | Univ California | Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation |
| US5767134A (en) * | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
| WO2000017334A2 (en) | 1998-09-23 | 2000-03-30 | Ludmila Solomin | Analysis of ligand activated nuclear receptors i(in vivo) |
| AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| CA2368234A1 (en) | 1999-03-26 | 2000-10-05 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| BR0011753A (pt) | 1999-06-18 | 2002-04-30 | Cv Therapeutics Inc | Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp |
| JP2004500332A (ja) | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| WO2001060818A1 (en) | 2000-02-14 | 2001-08-23 | Tularik Inc. | Lxr modulators |
| WO2001082917A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| EP1692127B1 (en) * | 2003-10-08 | 2008-07-02 | Smithkline Beecham Corporation | Triphenylethylene compounds as selective estrogen receptor modulators |
| WO2006066070A2 (en) * | 2004-12-17 | 2006-06-22 | Nps Pharmaceuticals, Inc. | Prodrug constructs of pyrimidinone compounds as calcilytics |
| CN101248048B (zh) * | 2005-06-27 | 2013-08-28 | 埃克塞利希斯专利有限责任公司 | 吡唑基lxr调节剂 |
| NZ564916A (en) * | 2005-06-27 | 2011-03-31 | Exelixis Inc | Imidazole based LXR modulators |
| KR20090094125A (ko) * | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| EP2139847A1 (en) * | 2007-03-05 | 2010-01-06 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies |
| SI2435410T1 (sl) | 2009-05-28 | 2017-06-30 | Bristol-Myers Squibb Company | Lxr modulatorji |
-
2012
- 2012-03-23 TW TW101110267A patent/TW201242953A/zh unknown
- 2012-03-23 AR ARP120100996A patent/AR088728A1/es not_active Application Discontinuation
- 2012-03-26 WO PCT/US2012/030499 patent/WO2012135082A1/en not_active Ceased
- 2012-03-26 US US14/006,980 patent/US8901106B2/en active Active
- 2012-03-26 JP JP2014501296A patent/JP2014510110A/ja active Pending
- 2012-03-26 CN CN201280014836.6A patent/CN103443082B/zh not_active Expired - Fee Related
- 2012-03-26 ES ES12711739.8T patent/ES2548050T3/es active Active
- 2012-03-26 EP EP12711739.8A patent/EP2688871B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510110A5 (enExample) | ||
| JP2014507446A5 (enExample) | ||
| CL2013001340A1 (es) | Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades. | |
| JP2013525444A5 (enExample) | ||
| JP2015516989A5 (enExample) | ||
| JP2014221779A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2015517579A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| WO2015002513A3 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
| JP2013522326A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| CL2015000946A1 (es) | Compuestos derivados de quinolinilo unidos a fenilo; composicion farmaceutica y su proceso de elaboracion; un metodo para tratar o mejorar un sindrome trastorno, o enfermedad inflamatoria mediada por ror-gamma-t, tal como artritis reumatoide, psoriasis, enfermedad de crohn, entre otras. | |
| JP2016540015A5 (enExample) | ||
| JP2013532687A5 (enExample) | ||
| WO2015066426A3 (en) | Angiopoietin-based interventions for treating cerebral malaria | |
| JP2012519182A5 (enExample) | ||
| JP2013523623A5 (enExample) | ||
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| JP2015516419A5 (enExample) |